Maximizing benefits of the levodopa/carbidopa intestinal gel: Systematic considerations, challenging convention and individualizing approaches

Abstract

The levodopa/carbidopa intestinal gel (LCIG) is an efficacious treatment for Parkinson disease. The initiation and management of the LCIG requires a streamlined approach that takes into account patient heterogeneity. In this article we outline an over arching approach to this while highlighting steps that could be potentially modified in each individual, with the ultimate goal of achieving ideal clinical outcomes.